ACCURATE Study for Subjects With Dry Eyes

Overview

To determine treatment and imaging outcomes in bilateral ocular surface disease management with an intracanalicular dexamethasone (0.4 mg) insert compared to standard topical over-the-counter artificial tears lubrication management

Full Title of Study: “Randomized Self-Controlled Treatment With an Intracanalicular Dexamethasone Insert Compared to Topical Over the Counter Lubrication Therapy in Patients With Bilateral Ocular Surface Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 30, 2021

Detailed Description

This study will evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert and patient administered artificial tears prn compared to patient administered artificial tears prn (control) in patients with bilateral ocular surface dry eye disease. The study is a self-controlled design and includes multiple objective, measureable, and quantifiable endpoints to best determine an objective response to treatment in patient eyes randomized to either the insert plus prn artificial tears or artificial tears prn control. To aid in ensuring best possible masking, DEXTENZA is best visualized with blue light and yellow filter and therefore visualization will not be assessed until final visit following all measures.

Interventions

  • Drug: Dextenza 0.4Mg Intracanalicular Insert
    • all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion
  • Other: Over the counter Artificial tears
    • over the counter artificial tears PRN at patient discretion

Arms, Groups and Cohorts

  • Experimental: Dextenza
    • Treatment Arm-Dextenza insertion lower lid punctum at time of screening and use of OTC artificial tears as needed
  • Active Comparator: Over the counter Artificial tears
    • Controlled arm: continuation of OTC artificial tears no placement of Dextenza intracanular insert

Clinical Trial Outcome Measures

Primary Measures

  • Determine effect of dexamethasone insert over artificial tears
    • Time Frame: 1 month
    • To determine the effect of dexamethasone insert plus over-the-counter artificial tears prn compared to over the counter artificial tears prn from Baseline at Week 2 (at 8 am, 12 pm and 4 pm) as measured by iTrace and IOL Master 700: and comfort of dry eyes using the OSDI scale and reading scores

Secondary Measures

  • OSDI scores
    • Time Frame: 1 month
    • comfort of dry eyes using the OSDI scale and reading scores, scores are from the SPEED questionnaire. scale from 0-3 0-Never 1- Sometime 2-Often 3-Constant for the symptoms

Participating in This Clinical Trial

Inclusion Criteria

A patient's study eye must meet the following criteria to be eligible for inclusion in the study:

  • Age 18 years and older – Demonstrate objective signs of Ocular Surface Disease (OSD) or – Demonstrate symptoms of OSD determined by a standardized questionnaire – No other corneal pathology to create unknown variability Exclusion Criteria:

A patient who meets any of the following criteria in either eye will be excluded from the study:

  • History of using topical steroids or other anti-inflammatory drops within 6 months of the study – History of corticosteroid implant (Ozurdex or Iluvien) or intravitreal steroid use for macular disease in last 12 months – History or current use of oral steroids or immunosuppressants – Active ocular infection – History of HSV – History corneal refractive surgery – Uncontrolled Glaucoma

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • The Eye Centers of Racine and Kenosha
  • Provider of Information About this Clinical Study
    • Principal Investigator: Pam Lightfield, I. Paul Singh, M.D. Principal Investigator – The Eye Centers of Racine and Kenosha
  • Overall Official(s)
    • Inder P Singh, M.D., Principal Investigator, President
  • Overall Contact(s)
    • Pam Lightfield, (262) 637-0500, plightfield@amazingeye.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.